Navigation Links
Corgenix Reports Second Quarter Fiscal 2010 Financial Results
Date:2/11/2010

DENVER, Feb. 11 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its 2nd quarter Form 10-Q and reported its financial results. The report disclosed that the company's revenues slightly declined during the quarter but slightly increased for the six months ended December 31, 2009. Some of the results highlighted by the report are as follows:

  • Revenues for the quarter decreased $35,574 or 1.8% vs. the prior year's comparable quarter
  • Total operating expenses decreased $147,774 or 12.2% vs. the prior year's comparable quarter
  • Operating income for the quarter was $12,395 vs. an operating loss of $56,223 for the prior year's comparable quarter
  • Net loss decreased to $83,841 or 68.8% in the current quarter from $268,374 in the prior year's comparable quarter

Douglass Simpson, Corgenix CEO and President, stated, "Compared to the prior year, revenues softened slightly in the second quarter, largely due to a decrease in our private label (OEM) and contract manufacturing business sectors, partially offset by slight growth in our direct product sales. We have recently added new contract manufacturing customers and are continuing to focus on the expansion and strengthening of this segment of our business."

The company further noted that the financial performance for the quarter was not as strong as expected, with continued weakness in core product revenue. The company continues to remain hopeful that Fiscal Year 2010 revenues will exceed those of the prior fiscal year, even though there can be no assurance that this will be the case.

Second Quarter 2010 Conference Call Details

Corgenix invites all those interested in hearing management's discussion of second quarter results to join a shareholders conference call on Thursday, February 11, 2010, at 4:00 PM EST (2:00 PM MST). Interested parties can join the call by dialing (800) 862-9098. International participants may access the call by dialing +1 785-424-1051. The conference code is "CORGENIX". A replay will be available for 30 days following the call by dialing (800) 283-4641 for domestic participants and +1 402-220-0851 for international participants.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

    
    
    
                           SUMMARY OF FINANCIAL HIGHLIGHTS
      ($000 of U.S. dollars except shares outstanding and per share amounts)
    
                    CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES
                                   OPERATIONAL DATA
    
                       Three Months Ended              Six Months Ended
                       ------------------              ----------------
                  December 31,     December 31,   December 31,    December 31,
                       2009            2008           2009            2008
                   (unaudited)     (unaudited)    (unaudited)     (unaudited)
                   -----------     -----------    -----------     -----------
    Net sales          $1,959          $1,995         $4,004          $3,997
    Gross
     profit             1,075           1,154          2,191           2,261
    Total
     operating
     expenses           1,063           1,210          2,094           2,411
    Operating
     income
     (loss)                12             (56)            96            (150)
    Net loss              (84)           (268)           (91)           (609)
    Basic and
     diluted
     loss per
     share             $(0.00)         $(0.01)        $(0.00)         $(0.02)
    Diluted
     shares
     outstanding   31,033,209      30,280,155     30,669,532      30,186,124
    
     
    
    
                              SUMMARY BALANCE SHEET DATA
                                    (in thousands)
    
                                   December 31, 2009     June 30, 2009
                                      (unaudited)         (audited)
                                       ----------         ---------
    Cash                                   $662              $785
    Working capital                       2,043             2,013
    Total assets                          6,367             6,906
    Long-term debt                          607               744
    Total stockholders' equity            3,052             3,113
    
    

SOURCE Corgenix Medical Corporation

RELATED LINKS
http://www.corgenix.com

'/>"/>

SOURCE Corgenix Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09
2. Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program
3. Corgenix to Host Conference Call to Discuss Fiscal 2010 First Quarter Results
4. Corgenix Reports Financial Results for First Quarter of Fiscal 2010
5. Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM)
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... SAN FRANCISCO, Calif. , May 19, 2016 /PRNewswire/ ... a biopharmaceutical company developing novel therapeutics for the treatment ... announced that new GBT440 data will be presented in ... 21 st Congress in Copenhagen ... ongoing Phase 1/2 GBT440-001 study in sickle cell disease ...
(Date:5/19/2016)... 2016 BioLineRx Ltd. (NASDAQ/TASE: BLRX) ... treatment of multiple cancer and hematological indications, will be ... abstract titled " Clinical response in relapsed/refractory AML patients ... BL-8040, a potent CXCR4 antagonist; results of a Phase ... at the European Hematology Association 21st Congress, to be ...
(Date:5/19/2016)... CAMBRIDGE, Massachusetts , May 19, 2016 ... pharmaceuticals and diagnostics based on the gut microbiome, is pleased ... Cambridge, MA to support its operations ... office is located at Kendall Square, the heart of ... global hub for transforming scientific insights into new drugs. The ...
Breaking Medicine Technology:
(Date:5/24/2016)... Linda, CA (PRWEB) , ... May 24, 2016 ... ... fluorescent cell imaging; high content imaging; multiplex immunoassays are widely used for cell ... important for labs to maximize their quality and efficiency in these areas. , ...
(Date:5/23/2016)... ... 23, 2016 , ... On the occasion of his 25th Anniversary of changing ... loss process: , New patients have a consultation and evaluation (done by Dr. Ferdico ... , Body Composition Analysis, There are 15 things that each patient gets checked for, ...
(Date:5/23/2016)... ... 23, 2016 , ... According to an article published May 11th ... birth of her son, Rockwell Lloyd Liu, and notes that gestational surrogacy helped make ... Bill” star explains that, as a career oriented single woman, gestational surrogacy made parenthood ...
(Date:5/23/2016)... ... May 23, 2016 , ... NYDNRehab, a New York City-based ... athletes. This is the first time this type of technology, which was developed by ... to the public in New York. , With over 10 million sport injuries ...
(Date:5/23/2016)... ... May 23, 2016 , ... California State University Northridge ... quality of life and is currently focusing on ways to improve how people ... tested through research to find out whether watching them could have a significant ...
Breaking Medicine News(10 mins):